https://doi.org/10.55788/dcba1289
Cognitive impairment has been reported in 81% and 21% of patients at 3 and 6 months after SARS-CoV-2 infection, respectively [1,2]. Psychiatric disturbance is present in 56% after 1 month and in 25% after 6 months [3,4]. Proposed pathogenic contributors are direct cerebral viral invasion and cellular damage, systemic inflammation through cytokine release, and cerebral microvascular changes [5]. Neuropathological studies have shown pronounced microglia activation and microthrombosis within white matter, mainly in the brain stem. Concerns about long-lasting neurological consequences of COVID-19 are growing, but there is a lack of longitudinal studies with long-term follow-up and structured neuropsychological assessments, and there is a complete lack of EEG studies focused on the post-COVID-19 phase.
Dr Giordano Cecchetti (Vita-Salute San Raffaele University, Italy) and colleagues set up a study to explore cognitive, EEG, and MRI features in COVID-19 survivors up to 10 months after hospital discharge [6,7]. Patients (n=49) with a recent diagnosis of COVID-19 underwent neuropsychological assessments investigating the main cognitive domains (global cognition, executive functions, memory, visuospatial functions, language) and 19-channel EEG within 2 months after hospital discharge; 33 patients repeated this within 10 months. A brain MRI was additionally performed at baseline in 36 participants. Of the 49 participants, 42 (86%) were treated as inpatients and 13 (27%) required non-invasive mechanical ventilation (NIMV).
Two months after SARS-CoV-2 infection, 53% of patients had cognitive impairment (16% executive impairment, 6% memory impairment, 6% visual-spatial impairment, 25% multi-domain impairment) and 28% showed psychopathological disturbance (10% depression, 12% PTSD, 6% depression + PTSD). Executive dysfunction correlated with the severity of the acute-phase respiratory distress, which was measured using the National Early Warning Score (NEWS). After 10 months, the percentage of patients with cognitive impairment had decreased to 36% (3% executive impairment, 6% memory impairment, 6% visual-spatial impairment, 21% multi-domain impairment), whereas the percentage with psychiatric symptoms remained the same (6% depression, 18% PTSD, 9% depression + PTSD). Patients with dysgeusia/hyposmia during acute-phase COVID-19 showed a significantly slower recovery of cognition than those without. A lower EEG delta band at baseline predicted worse cognitive functioning at follow-up. MRI analysis revealed prominent cerebrovascular alterations in COVID-19 patients, correlating with worse memory function at baseline and with the total number of cardiovascular risk factors. On the other hand, no relation with severity of acute COVID-19 was found. Whether the observed alterations were directly linked to the infection or rather to its consequences is yet to be determined, as well as their reversibility.
- Mazza MG, et al. Brain Behav Immun. 2021;94:138â147.
- Del Brutto OH, et al. Eur J Neurol. 2021;28(10):3245â3253.
- Mazza MG, et al. Brain Behav Immun. 2020;89:594â600.
- Huang C, et al. Lancet. 2021;397(10270):220â232.
- Heneka MT, et al. Alzheimers Res Ther. 2020;12(1):69.
- Cecchetti G, et al. Cognitive, EEG and MRI features of COVID-19 survivors: a 10-month study. Contemporary Clinical Issues, AAN 2022, 02â07 April, Seattle, USA.
- Cecchetti G, et al. J Neurol. Mar 6, 2022. DOI: 10.1007/s00415-022-11047-5.
Copyright ©2022 Medicom Medical Publishers
Posted on
Previous Article
« Interview with Prof. Natalia Rost Next Article
Letter from the Editor »
« Interview with Prof. Natalia Rost Next Article
Letter from the Editor »
Table of Contents: AAN 2022
Featured articles
Letter from the Editor
Interview with Prof. Natalia Rost
Alzheimerâs Disease and Other Dementias
Targeting senescent cells to treat age-related diseases
Cardiorespiratory fitness protects against dementia
Safety and effects of bosutinib in Lewy body dementia
Epilepsy
âWomen with epilepsy should be encouraged to breastfeedâ
Fenfluramine: possible new treatment for Lennox-Gastaut syndrome
Laser interstitial thermal therapy for refractory epilepsy
Migraine
Migraine may be an important obstetric risk factor
Intranasal zavegepant safe and well tolerated in healthy adults
Telemedicine during COVID-19 pandemic highly appreciated
Multiple Sclerosis
Ublituximab versus teriflunomide in relapsing MS patients
Ketogenic diet may improve disability and quality of life
Favourable additional safety data for ofatumumab
Predicting new T2 lesions using a machine learning algorithm
Evobrutinib reduces volume of slowly expanding lesions
Sustained long-term efficacy and safety of satralizumab in NMOSD
Muscle and Neuro-Muscular Disorders
Ravulizumab in patients with generalised myasthenia gravis
Gene therapy effective in older patients with spinal muscular atrophy
Losmapimod for facioscapulohumeral muscular dystrophy
SRP-9001 for treating patients with Duchenne muscular dystrophy
Cerebrovascular Disease and Stroke
Intravenous thrombolysis after ischaemic stroke: When in doubt, leave it out?
Better outcomes with mechanical thrombectomy in elderly stroke patients
Plasma NfL levels associated with cardiovascular risk
Non-invasive vagus nerve stimulation for acute stroke
Parkinsonâs Disease
Prasinezumab in Parkinsonâs disease: delayed-start analysis of PASADENA trial
IPX203 versus immediate release carbidopa-levodopa
Impact of COVID-19 public health interventions
COVID-19
Cognitive, EEG, and MRI features in COVID-19 survivors
Neurological manifestations of COVID-19 worsen prognosis
New evidence for biological basis of âCOVID-19 brain fogâ
Related Articles
August 18, 2021
First evidence of brainstem involvement in COVID-19
August 12, 2021
New GI symptoms common among IBD patients with COVID-19
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com